Kura Oncology to Host Virtual Investor Event on December 5, 2020

Rhea-AI Summary

Kura Oncology will host a virtual investor event on December 5, 2020, at 2:00 p.m. ET to discuss preliminary clinical data regarding its menin inhibitor, KO-539, following its presentation at the 62nd American Society of Hematology (ASH) Annual Meeting. The event will feature Kura's management team and investigators from the ongoing KOMET-001 trial. A live video webcast will be available on Kura's website, with an archived replay accessible after the event.

Event to follow presentation of preliminary clinical data for menin inhibitor KO-539 at ASH

SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event to provide a review of the Company’s oral, potent and selective menin inhibitor, KO-539, following the oral presentation of preliminary clinical data at the 62nd American Society of Hematology (ASH) Annual Meeting. The event will feature members of the Kura management team along with two of the investigators from KOMET-001, an ongoing Phase 1/2A clinical trial of KO-539. The virtual event will take place at 2:00 p.m. ET / 11:00 a.m. PT on Saturday, December 5, 2020.

A live video webcast of the event will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available shortly after the conclusion of the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed or refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

What is the purpose of Kura Oncology's virtual investor event on December 5, 2020?

The event aims to review preliminary clinical data for the menin inhibitor KO-539 following its presentation at the ASH Annual Meeting.

When will Kura Oncology's virtual investor event take place?

The event is scheduled for December 5, 2020, at 2:00 p.m. ET.

Where can I watch Kura Oncology's virtual investor event?

The event will be streamed live on Kura's website, with an archived replay available later.

What clinical trial is associated with Kura Oncology's KO-539?

KO-539 is part of the KOMET-001 Phase 1/2A clinical trial for acute myeloid leukemia.

Who will be speaking at Kura Oncology's investor event?

Kura's management team and investigators from the KOMET-001 trial will be featured at the event.